Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 11, 2020

SELL
$62.63 - $80.22 $206,303 - $264,244
-3,294 Closed
0 $0
Q4 2019

Feb 10, 2020

SELL
$61.62 - $67.78 $1,848 - $2,033
-30 Reduced 0.9%
3,294 $214,000
Q3 2019

Nov 08, 2019

SELL
$62.51 - $69.0 $27,629 - $30,498
-442 Reduced 11.74%
3,324 $211,000
Q2 2019

Aug 01, 2019

SELL
$61.87 - $69.38 $6,187 - $6,938
-100 Reduced 2.59%
3,766 $254,000
Q1 2019

May 02, 2019

SELL
$62.53 - $70.05 $4,377 - $4,903
-70 Reduced 1.78%
3,866 $251,000
Q4 2018

Feb 19, 2019

SELL
$60.54 - $79.0 $10,594 - $13,825
-175 Reduced 4.26%
3,936 $246,000
Q3 2018

Nov 09, 2018

SELL
$71.28 - $78.92 $19,245 - $21,308
-270 Reduced 6.16%
4,111 $317,000
Q2 2018

Aug 13, 2018

BUY
$64.88 - $75.68 $284,239 - $331,554
4,381 New
4,381 $310,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $83.6B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Lcnb Corp Portfolio

Follow Lcnb Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lcnb Corp, based on Form 13F filings with the SEC.

News

Stay updated on Lcnb Corp with notifications on news.